Mural Oncology (MURA) Q2 Loss Widens 49%

Mural Oncology (NASDAQ:MURA), a biotechnology company that previously focused on developing immunotherapy drugs for cancer, announced its second quarter 2025 results on August 4, 2025. The critical news: Mural Oncology fully discontinued all research and development (R&D) programs, including its lead candidate nemvaleukin alfa, and has since begun exploring strategic alternatives such as a sale or liquidation, as announced on April 15, 2025. The quarter saw a net loss per share (GAAP) of ($2.78), far worse than the consensus estimate of a ($1.00) loss, with the shortfall explained by one-time restructuring and impairment costs totaling $17.5 million. Management’s guidance now centers exclusively on preserving cash, closing out a challenging and transitional quarter for Mural Oncology. Source: Analyst estimates for the quarter provided by FactSet. Mural Oncology historically operated as a clinical-stage biotechnology firm specializing in immune-based therapies targeting cancer. Its lead asset was nemvaleukin alfa, a modified protein intended to stimulate the immune system against tumors. Until this quarter, the company focused on both clinical and preclinical programs in oncology, pursuing specialized indications such as mucosal melanoma and platinum-resistant ovarian cancer.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool